BRPI0815948A2 - "compostos heterocíclicos como antagonistas de receptorncrth2" - Google Patents
"compostos heterocíclicos como antagonistas de receptorncrth2"Info
- Publication number
- BRPI0815948A2 BRPI0815948A2 BRPI0815948A BRPI0815948A BRPI0815948A2 BR PI0815948 A2 BRPI0815948 A2 BR PI0815948A2 BR PI0815948 A BRPI0815948 A BR PI0815948A BR PI0815948 A BRPI0815948 A BR PI0815948A BR PI0815948 A2 BRPI0815948 A2 BR PI0815948A2
- Authority
- BR
- Brazil
- Prior art keywords
- antagonists
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99829807P | 2007-10-10 | 2007-10-10 | |
| PCT/US2008/079303 WO2009049021A1 (en) | 2007-10-10 | 2008-10-09 | Heterocyclic compounds as crth2 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0815948A2 true BRPI0815948A2 (pt) | 2019-09-24 |
Family
ID=40549546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0815948A BRPI0815948A2 (pt) | 2007-10-10 | 2008-10-09 | "compostos heterocíclicos como antagonistas de receptorncrth2" |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8772312B2 (pt) |
| EP (1) | EP2197438B1 (pt) |
| JP (2) | JP2011500584A (pt) |
| KR (2) | KR101442663B1 (pt) |
| CN (1) | CN101896178B (pt) |
| AU (1) | AU2008310874B2 (pt) |
| BR (1) | BRPI0815948A2 (pt) |
| CA (1) | CA2700824C (pt) |
| ES (1) | ES2548577T3 (pt) |
| IL (1) | IL204823A0 (pt) |
| RU (1) | RU2451019C2 (pt) |
| WO (1) | WO2009049021A1 (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010008864A2 (en) | 2008-06-24 | 2010-01-21 | Amira Pharmaceuticals, Inc. | Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors |
| CA2736571A1 (en) * | 2008-09-22 | 2010-03-25 | Merck Frosst Canada Ltd. | Azaindole derivatives as crth2 receptor antagonists |
| WO2010031183A1 (en) | 2008-09-22 | 2010-03-25 | Merck Frosst Canada Ltd. | Indole derivatives as crth2 receptor antagonists |
| GB2465062B (en) * | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| SG176628A1 (en) | 2009-06-05 | 2012-01-30 | Link Medicine Corp | Aminopyrrolidinone derivatives and uses thereof |
| EP2558447B1 (en) | 2010-03-22 | 2014-09-17 | Actelion Pharmaceuticals Ltd. | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| WO2012107364A1 (en) * | 2011-02-07 | 2012-08-16 | Scipharm Sàrl | Novel composition for the treatment of cystic fibrosis |
| CA2830204C (en) | 2011-04-14 | 2019-04-09 | Actelion Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| EA030159B1 (ru) | 2014-03-17 | 2018-06-29 | Идорсиа Фармасьютиклз Лтд | Производные азаиндолуксусной кислоты и их применение в качестве модуляторов рецепторов простагландина d2 |
| JP6484644B2 (ja) | 2014-03-18 | 2019-03-13 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | アザインドール酢酸誘導体及びプロスタグランジンd2受容体調節剤としてのそれらの使用 |
| US20180021302A1 (en) * | 2015-02-13 | 2018-01-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
| WO2017005764A1 (en) * | 2015-07-07 | 2017-01-12 | Intervet International B.V. | A process to make tricycloketone intermediates of crth2 antagonists |
| WO2017005759A1 (en) * | 2015-07-07 | 2017-01-12 | Intervet International B.V. | A process to make azaindole derivatives |
| UA123156C2 (uk) | 2015-09-15 | 2021-02-24 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА ФОРМА (S)-2-(8-((5-ХЛОРПІРИМІДИН-2-ІЛ)(МЕТИЛ)АМІНО)-2-ФТОР-6,7,8,9-ТЕТРАГІДРО-5H-ПІРИДО[3,2-b]ІНДОЛ-5-ІЛ)ОЦТОВОЇ КИСЛОТИ, ЇЇ ЗАСТОСУВАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ |
| RU2744976C1 (ru) * | 2015-09-29 | 2021-03-17 | Новартис Аг | Способ получения 1-(4-метансульфонил-2-трифторметилбензил)-2-метил-1н-пирроло[2,3-b]пиридин-3-ил-уксусной кислоты |
| JOP20190223A1 (ar) * | 2017-04-01 | 2019-09-26 | Novartis Ag | عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك |
| WO2020143781A1 (zh) * | 2019-01-10 | 2020-07-16 | 石药集团中奇制药技术(石家庄)有限公司 | 作为crth2受体拮抗剂的杂环化合物的晶型 |
| CN113330013B (zh) * | 2019-01-10 | 2022-12-27 | 石药集团中奇制药技术(石家庄)有限公司 | 杂环化合物盐及其应用 |
| WO2020233713A1 (zh) * | 2019-05-22 | 2020-11-26 | 石药集团中奇制药技术(石家庄)有限公司 | 杂环化合物及其盐的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4279561B2 (ja) * | 2001-05-23 | 2009-06-17 | メルク フロスト カナダ リミテツド | プロスタグランジンD2受容体拮抗薬としてのジヒドロピロロ[1,2−a]インドールおよびテトラヒドロピリド[1,2−a]−インドール誘導体 |
| PL376440A1 (en) * | 2002-10-30 | 2005-12-27 | Merck Frosst Canada Ltd. | Pyridopyrrolizine and pyridoindolizine derivatives |
| CN1732171A (zh) * | 2002-10-30 | 2006-02-08 | 麦克弗罗斯特(加拿大)公司 | 吡啶并吡咯里嗪和吡啶并吲嗪衍生物 |
| ES2304010T3 (es) | 2004-03-11 | 2008-09-01 | Actelion Pharmaceuticals Ltd. | Derivados de tetrahidropiridoindol. |
| JP4708885B2 (ja) * | 2005-07-06 | 2011-06-22 | 日本電気株式会社 | 符号化装置、携帯端末装置及びそれらに用いる画素色情報符号化方法 |
| CA2618550C (en) * | 2005-08-12 | 2013-12-17 | Merck Frosst Canada Ltd. | Indole derivatives as crth2 receptor antagonists |
| US20110112134A1 (en) | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
-
2008
- 2008-10-09 AU AU2008310874A patent/AU2008310874B2/en not_active Ceased
- 2008-10-09 KR KR1020107010092A patent/KR101442663B1/ko not_active Expired - Fee Related
- 2008-10-09 RU RU2010117156/04A patent/RU2451019C2/ru active
- 2008-10-09 US US12/681,356 patent/US8772312B2/en active Active
- 2008-10-09 KR KR1020137011440A patent/KR20130069840A/ko not_active Ceased
- 2008-10-09 BR BRPI0815948A patent/BRPI0815948A2/pt not_active IP Right Cessation
- 2008-10-09 JP JP2010529022A patent/JP2011500584A/ja active Pending
- 2008-10-09 EP EP08838211.4A patent/EP2197438B1/en active Active
- 2008-10-09 ES ES08838211.4T patent/ES2548577T3/es active Active
- 2008-10-09 WO PCT/US2008/079303 patent/WO2009049021A1/en not_active Ceased
- 2008-10-09 CA CA2700824A patent/CA2700824C/en active Active
- 2008-10-09 CN CN2008801092963A patent/CN101896178B/zh active Active
-
2010
- 2010-03-28 IL IL204823A patent/IL204823A0/en unknown
-
2013
- 2013-06-19 JP JP2013128863A patent/JP5680146B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2700824A1 (en) | 2009-04-16 |
| AU2008310874A1 (en) | 2009-04-16 |
| JP2011500584A (ja) | 2011-01-06 |
| JP2013209425A (ja) | 2013-10-10 |
| EP2197438B1 (en) | 2015-07-15 |
| AU2008310874B2 (en) | 2012-03-15 |
| CN101896178B (zh) | 2013-11-20 |
| EP2197438A4 (en) | 2011-10-12 |
| RU2010117156A (ru) | 2011-11-20 |
| HK1147674A1 (en) | 2011-08-19 |
| IL204823A0 (en) | 2010-11-30 |
| ES2548577T3 (es) | 2015-10-19 |
| JP5680146B2 (ja) | 2015-03-04 |
| KR20130069840A (ko) | 2013-06-26 |
| KR20100065398A (ko) | 2010-06-16 |
| RU2451019C2 (ru) | 2012-05-20 |
| US8772312B2 (en) | 2014-07-08 |
| WO2009049021A1 (en) | 2009-04-16 |
| US20100222270A1 (en) | 2010-09-02 |
| CA2700824C (en) | 2013-12-10 |
| EP2197438A1 (en) | 2010-06-23 |
| CN101896178A (zh) | 2010-11-24 |
| KR101442663B1 (ko) | 2014-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0815948A2 (pt) | "compostos heterocíclicos como antagonistas de receptorncrth2" | |
| BRPI0718266A2 (pt) | Compostos heterocíclicos como agentes anti-inflamatórios. | |
| BRPI0717937A2 (pt) | Compostos de pirazona como antagonistas do receptor mineralocorticóide | |
| BRPI0910229A2 (pt) | Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos | |
| BRPI0922904A2 (pt) | "compostos" | |
| BRPI0814426A2 (pt) | Compostos heterocíclicos úteis como inibidores de mk2 | |
| DE602008003015D1 (de) | Heterocyclische spiroverbindungen | |
| BRPI0813768A2 (pt) | Derivados de benzazepina úteis como antagonistas de vasopressina | |
| BRPI0916218A2 (pt) | compostos heterocíclicos como composições praguicidas | |
| BRPI0810462A2 (pt) | Derivados de quinolina-carboxamida como antagonistas de p2y12 | |
| BRPI0916233A2 (pt) | compostos heterocíclicos antivirais | |
| BRPI0914772A2 (pt) | compostos heterocíclicos 1,2-dissubstituídos | |
| BRPI1015540A2 (pt) | ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750'' | |
| BRPI0811280A2 (pt) | Compostos amino-heterocíclicos | |
| BRPI0718509A2 (pt) | compostos orgânicos heterocíclicos | |
| ATE502948T1 (de) | Substituierte bicyclolactamverbindungen | |
| BRPI0815042A2 (pt) | Compostos de pirazol | |
| BRPI0918045A2 (pt) | compostos de carboxamida heterocíclicos | |
| BRPI0906705A2 (pt) | Composto heterocíclicos | |
| BRPI0909157A2 (pt) | compostos heterocíclicos como antagonistas de receptores de adenosina | |
| HRP20151108T1 (xx) | Antagonisti nogo-receptora | |
| BRPI0718494A2 (pt) | Derivado de fenilsulfamoil benzamida como antagonistas de bradicinina | |
| BRPI0817562A2 (pt) | derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis | |
| BRPI1007878A2 (pt) | "compostos inseticidas" | |
| BRPI0817061A2 (pt) | Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |